 |
Top 80 medical and healthcare startups in Canada
Oct 24, 2024 | By Jason Kwon | 16 |
1
Funding: $210.5M
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
2
Funding: CA$3.8M
For a half century, ophthalmic surgeons have envisioned an intraocular lens capable of restoring eyesight at all distances. Ocumetics Technology Corporation was founded to achieve this goal. Employing state-of-the art materials and production techniques, Ocumetics Technology Corporation is in the process of developing a highly advanced intraocular lens, one that is capable of restoring clear vision at all distances, without glasses or contact lenses, and without the visual quality problems that have plagued current accommodative and multifocal intraocular lens designs.
For a half century, ophthalmic surgeons have envisioned an intraocular lens capable of restoring eyesight at all distances. Ocumetics Technology Corporation was founded to achieve this goal. Employing state-of-the art materials and production techniques, Ocumetics Technology Corporation is in the process of developing a highly advanced intraocular lens, one that is capable of restoring clear vision at all distances, without glasses or contact lenses, and without the visual quality problems that have plagued current accommodative and multifocal intraocular lens designs.
4
Funding: $887M
AbCellera Biologics offers development of antibody therapeutics to improve patient outcomes.
AbCellera Biologics offers development of antibody therapeutics to improve patient outcomes.
5
Funding: $322.6M
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
6
Funding: $267M
Fullscript is a supplement dispensing platform and patient adherence tool that supports practitioners at the point of care and beyond.
Fullscript is a supplement dispensing platform and patient adherence tool that supports practitioners at the point of care and beyond.
7
Funding: $251.7M
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
8
Funding: $250M
Profound Medical Inc is a medical device company providing Magnetic Resonance guided ablation procedure for prostate care.
Profound Medical Inc is a medical device company providing Magnetic Resonance guided ablation procedure for prostate care.
9
Funding: $236.7M
Deep Genomics brings together world-leading expertise in machine learning and genome biology. We’re inventing a new generation of computational technologies that predict what will happen within a cell when DNA is altered by genetic variation, whether natural or therapeutic. Our systems predict the molecular effects of genetic variation, opening a new and exciting path to discovery for disease diagnostics and therapies.
Deep Genomics brings together world-leading expertise in machine learning and genome biology. We’re inventing a new generation of computational technologies that predict what will happen within a cell when DNA is altered by genetic variation, whether natural or therapeutic. Our systems predict the molecular effects of genetic variation, opening a new and exciting path to discovery for disease diagnostics and therapies.
10
Funding: $225M
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
11
Funding: $208.1M
Medicago is a biotechnology company focused on the research, development, production, and commercialization of vaccines in Canada. Acquired by Mitsubishi Tanabe Pharma
Medicago is a biotechnology company focused on the research, development, production, and commercialization of vaccines in Canada. Acquired by Mitsubishi Tanabe Pharma
12
Funding: $171.1M
League is a digital health platform that connects people to a comprehensive network of health services and benefits.
League is a digital health platform that connects people to a comprehensive network of health services and benefits.
13
Funding: $148.3M
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
14
Funding: $141.4M
Kintara Therapeutics is engaged in developing and commercializing therapies for the treatment of cancer patients.
Kintara Therapeutics is engaged in developing and commercializing therapies for the treatment of cancer patients.
15
Funding: $103M
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
16
Funding: $100.1M
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
17
Funding: $81.1M
Aspect Biosystems is an award-winning biotechnology company specializing in 3D bioprinting and tissue engineering. We bring together a multi-talented team of individuals to develop cutting-edge custom human tissue technology for use in the life sciences.
Aspect Biosystems is an award-winning biotechnology company specializing in 3D bioprinting and tissue engineering. We bring together a multi-talented team of individuals to develop cutting-edge custom human tissue technology for use in the life sciences.
18
Funding: $71.7M
Maple's mission is to tackle some of the world’s most meaningful issues in healthcare, starting with timely and convenient access to doctors and other healthcare providers – so that you can feel better, faster.
Maple's mission is to tackle some of the world’s most meaningful issues in healthcare, starting with timely and convenient access to doctors and other healthcare providers – so that you can feel better, faster.
19
Funding: $64.6M
Congruence Therapeutics is building a team of 'drug hunters' to go after rare disease targets
Congruence Therapeutics is building a team of 'drug hunters' to go after rare disease targets
20
Funding: €60.1M
AlayaCare is a start-up delivering a software solution and hardware ecosystem that allows homecare agencies to deliver mixed telehealth / visiting health solutions enabling empowered patients to live better while driving down the cost of care.
AlayaCare is a start-up delivering a software solution and hardware ecosystem that allows homecare agencies to deliver mixed telehealth / visiting health solutions enabling empowered patients to live better while driving down the cost of care.
